New pill combo could shrink lung tumors before surgery

NCT ID NCT06268210

Ongoing Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This Phase 2 trial tests the targeted drug lazertinib, alone or with chemotherapy, before surgery in 160 adults with EGFR-mutant non-small cell lung cancer (stages IB to IIIB). The goal is to see if these treatments can shrink tumors enough to improve surgical outcomes. Participants take the drugs for a few months before surgery and continue lazertinib for up to 3 years after.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lazertinib (a targeted cancer pill) with or without chemotherapy (pemetrexed and carboplatin)
What this could lead to: If successful, this could lead to a new treatment option that shrinks EGFR-mutant lung tumors before surgery, potentially improving long-term outcomes.
What could go wrong: This is a Phase 2 trial with only 160 participants, so results are preliminary. The treatment may not work better than current options, and side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Severance hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.